Insider Selling: Vericel (NASDAQ:VCEL) Director Sells $113,500.00 in Stock

Vericel Corporation (NASDAQ:VCEL) Director Robert Md Zerbe sold 2,500 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $45.40, for a total transaction of $113,500.00. Following the transaction, the director owned 32,995 shares in the company, valued at $1,497,973. The trade was a 7.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $54.62 on Monday. The firm has a market capitalization of $2.80 billion, a PE ratio of 85.35 and a beta of 1.08. The business has a 50 day simple moving average of $41.01 and a two-hundred day simple moving average of $38.90. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $55.60.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.21. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The firm had revenue of $85.37 million during the quarter, compared to analyst estimates of $77.95 million. During the same period last year, the company earned $0.10 EPS. Vericel’s quarterly revenue was up 26.5% compared to the same quarter last year. Equities research analysts expect that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Institutional Trading of Vericel

A number of large investors have recently modified their holdings of VCEL. MCF Advisors LLC grew its stake in Vericel by 293.0% in the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares in the last quarter. Ameritas Advisory Services LLC bought a new stake in Vericel during the 2nd quarter valued at $36,000. Allworth Financial LP bought a new stake in Vericel during the 2nd quarter valued at $60,000. Meeder Asset Management Inc. bought a new stake in Vericel during the 1st quarter valued at $61,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Vericel in the 2nd quarter worth $72,000.

Analysts Set New Price Targets

Several research firms have recently weighed in on VCEL. Truist Financial set a $65.00 target price on Vericel in a research report on Friday. TD Cowen upped their price target on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a research note on Thursday, July 30th. HC Wainwright raised their price target on shares of Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Wall Street Zen upgraded shares of Vericel from a “buy” rating to a “strong-buy” rating in a report on Saturday. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Vericel presently has an average rating of “Moderate Buy” and a consensus target price of $60.80.

Vericel News Roundup

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.